Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology tests and software for microbiology laboratories, announced the signing of a distribution agreement granting PALEX (https://www. palexmedical. com/) the rights to offer ABL Diagnostics products to laboratories in Spain.
The collaboration will be carried out through a close collaboration with ABL TherapyEdge SL Spain (a subsidiary of ABL Diagnostics). The technical and advertising teams of both companies will try to optimize the experience of users of laboratories that wish to implement ABL Diagnostics or Software kits in Spain.
As a passionate partner with more than 65 years of experience in the healthcare industry, Palex will be able to provide end-to-end answers based on NGS formulation innovation, in addition to providing ABL Diagnostics products to laboratories with select sequencing techniques, such as Sanger.
“Spain is the country where our DeepChek® generation was born thanks to a vital collaboration with key opinion leaders, industry and national institutions such as CDTI. This new partnership with Palex will strengthen our presence and will be an undeniable asset for laboratories interested in accessing our cutting-edge generation,” said Ronan Boulme, Director of GRC at ABL Diagnostics.
“Being able to offer sequencing-based answers to microbiology laboratories has a precedent since COVID-19. Through its network of suppliers, Palex is able to offer end-to-end answers to hospitals and laboratories interested in infectious disease control. “This collaboration with ABL Diagnostics and its Spanish subsidiary is a strategic asset for the company, we are proud to join forces and be able to spread the DeepChek® generation in Spain,” added Jaune Clariana, Head of In Vitro Diagnostics at PALEX.
The detailed terms of the deal were revealed.
***
ABOUT ABL DIAGNOSIS
ABL DIAGNOSTICS S. A. (ABLD) is a leading foreign company offering patented, state-of-the-art molecular biology tests and comprehensive responses for use in the detection of molecular polymerase chain reaction (PCR): UltraGene® and for DNA sequencing genotyping: DeepChek® (a very delicate, physically powerful and enduring technology that enables the exact identity of applicable genomic diversifications, such as single nucleotide polymorphisms (SNPs), amino acid mutations, quasi-species as variants of interest, already published or to be discovered in the future. , which influence disease prognosis, drug efficacy, pathogenic activity, etc. ).
These molecular biology products generate recurring revenue and cover one of the broadest portfolios of microbiology applications, which are developed year after year to meet market needs, with a number one focus on HIV (with CE-IVD-marked target-specific testing covering all applicable areas). genes used for the assessment of drug resistance, such as opposite transcriptase, protease, integrase, and with disruptive total genome kits), SARS-CoV-2 (with a CE-IVD-labeled total genome assay), tuberculosis (with a CE-IVD-labeled total genome assay) labeled multiplex assay targeting genes applicable to first-line resistance determination, new and second-line drugs), viral hepatitis B and C, 16s/18s RNA for taxonomy and microbiome analysis, and other viral and bacterial targets. Please refer to the ABL Diagnostics Team for more information on the registration reputation of ABL Diagnostics products in your jurisdiction.
ABL Diagnostics markets its full range of products internationally through its own sales team and through a network of exclusive suppliers active on all continents. ABL Diagnostics’ consumers are clinical pathology educational laboratories, personal reference laboratories, and researchers eager to implement cutting-edge technologies and physically. Powerful microbiological content that is expanding.
ABL Diagnostics also develops, manufactures and markets clinical specimen collection kits: MediaChek® and virtual responses such as Nadis®, a CE-marked electronic health record (EHR) formula used in France in more than two hundred hospitals caring for HIV-infected people or viral patients. Hepatitis.
ABL Diagnostics, headquartered in Woippy, is a public company indexed in compartment B of the Euronext Paris regulated market (Euronext: ABLD – ISIN: FR001400AHX6).
For more information, visit www. abldiagnostics. com
ABOUT PALEX
For more than 65 years, PALEX has generated responses that have made significant advances in the field of health, thanks to a philosophy of continuous improvement through innovation. Palex has been supported by Apax Partners since 2023 and Fremman. Capital since 2021.
At PALEX, technology is implemented in the fitness box to improve life and well-being. Constant innovation provides answers that help improve disease diagnosis, treatment, and patient follow-up.
To achieve this, PALEX will need to perceive the truth faced by healthcare professionals around the world in hospitals, medical centers, and study centers. PALEX allows technological innovation to introduce new responses in the health sector by adapting technological advances to the real situations of each hospital, branch and professional.
The pillars of PALEX are: first, to identify and compare technological inventions that can advance healthcare. Second, create a custom solution. Thirdly, to contribute day by day and proximity to ensure the implementation of the responses and their continuous improvement.
The Palex Group launched the first “Shiley” rotary disc center valve in 1969. In 1973, PALEX contributed decisively with its products and to the advancement of hemodialysis in Spain by being the first Spanish company to manufacture concentrates for dialysis.
In 1985, PALEX was the first company to introduce a patient monitoring formula to the market (via PATS software) and in 1988 began marketing the Jarvik® synthetic center and, two years later, began promoting autotransfusion in regimen vascular procedures.
In 1999, PALEX created the Key Accounts Division with the (at the time) cutting-edge objective of entering into full service agreements with leading hospitals, providing complex controlled hospital responses through a team of specialists.
In 2005, PALEX installed the first da Vinci® surgical robot in Spain. In 2007, the launch of the Berlin Heart and the implantation of the mechanical ventricular assist device INCOR. ®In 2009, PALEX brought the FIT colorectal cancer screening program to Spain and after ten years it has the company that collaborates in 21 of the 24 colorectal cancer screening systems in Spain. A year later, in 2010, PALEX brought the Oncotype DX® genomics platform for breast cancer.
In the following years, up to the present day, PALEX has participated, collaborated or led the emergence and progression of fitness responses such as the Smart Kanban® formula, the first implantation in Spain of a central valve without Perceval suture®, the formula of the Apoteca Chemo robot for prepared cytostatics or the first closed formula incorporated for cytostatic transfer, Equashield®, among others.
However, the demonstration of corporate commitment and culture is the maintenance of fruitful, long-term relationships with the corporations PALEX represents and their partners and customers.
CONTACTS
Diagnosing ABL
PALEX
Jaume ClarianaHead of Specialized UnitIn Vitro DiagnosticsTel: 34 6 39 88 94j. clariana@palex. es
FORWARD-LOOKING STATEMENT
This press release expressly or implicitly includes forward-looking statements about ABL Diagnostics and its business. These forward-looking statements are based on assumptions that ABL Diagnostics believes to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, that they are subject to dangers, by adding those set forth in the “Risk Factors” segment of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, which is located on the ABL Diagnostics online page (www. abldiagnostics. com) and adjustments in economic conditions, the money markets and the markets in which ABL Diagnostics operates. The forward-looking statements contained in this press release are also subject to dangers that ABL Diagnostics does not yet know or that are not of late. considered as curtains through ABL Diagnostics. La occurrence of some or all of those perils may merely cause ABL Diagnostics’ actual results, monetary condition, functionality or achievements to differ materially from those forward-looking statements.
This press release and the information contained herein do not and should not be construed as an offer or solicitation to sell or subscribe to, or a solicitation of, any order or invitation to buy or subscribe for shares of ABL Diagnostics in any country. This press release in certain countries may be a violation of applicable laws. The owners of this press release are informed of and comply with local restrictions.
No media outlet joined. Please contact ABL Diagnostics SA for information.
You read:
ABL Diagnostics chooses PALEX to offer NGS and Sanger genotyping programs to microbiology laboratories in Spain.